
In a phase I trial zzso zzso zzso was administered as oral capsules once a week to 51 adults with advanced mainly gastrointestinal solid zzso No fatal toxicity was observed at doses up to zzso zzso zzso zzso and zzso toxicity developed at zzso greater than or equal to zzso zzso No response to the therapy was zzso The plasma zzso of zzso zzso were measured in 4 of the zzso 

